文献速递泌尿生殖与妇科肿瘤放疗

中危前列腺癌男性患者雄激素剥夺治疗使用差异:全州放射肿瘤学质量联盟的结果

Variation in Androgen Deprivation Therapy Use Among Men With Intermediate-Risk Prostate Cancer: Results From a Statewide Radiation Oncology Quality Consortium.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-06-04

研究基于MROQC前瞻性纳入570例中危前列腺癌患者,发现46%计划使用ADT, favorable intermediate-risk为23.5%、unfavorable为56.3%(P<.001),机构间预测概率从15.4%到71.7%不等(P<.01),多因素分析显示grade group 3、≥50%阳性针数及PSA 10-20与ADT使用相关。

要点

  • 中危前列腺癌计划ADT使用率为46%(262/570),NCCN favorable intermediate-risk为23.5%(38/172),unfavorable为56.3%(224/398),P<.001。
  • 调整病例组合后,各机构计划ADT使用预测概率从15.4%(95%CI 5.4%-37.0%)到71.7%(95%CI 57.0%-82.9%),P<.01。
  • grade group 3(OR 4.60 [3.20-6.67])、≥50%阳性针数(OR 2.15 [1.43-3.25])、PSA 10-20(OR 1.87 [1.24-2.84])与ADT使用相关。

核心结论

  • 在全州联盟内,中危前列腺癌男性患者的计划ADT使用存在显著的机构间异质性。
  • 未来需识别最可能从ADT获益的患者,并制定策略以标准化适当使用。

研究设计与样本

  • 前瞻性队列研究,纳入2020年6月9日至2023年6月26日期间接受根治性放疗的局限性前列腺癌患者(n=815),使用标准化患者、医生和物理师表格收集数据。
  • 中危患者570例来自26家机构,主要结局为前瞻性定义的计划ADT使用,采用多因素分析和随机截距模型评估机构间差异。

主要发现

  • 计划ADT用于46%的中危男性(262/570),NCCN favorable intermediate-risk为23.5%(38/172),unfavorable为56.3%(224/398),P<.001。
  • 调整全州病例组合后,各机构计划ADT使用预测概率从15.4%(95%CI 5.4%-37.0%)到71.7%(95%CI 57.0%-82.9%),P<.01。
  • 多因素分析显示grade group 3(OR 4.60 [3.20-6.67])、≥50%阳性针数(OR 2.15 [1.43-3.25])、PSA 10-20(OR 1.87 [1.24-2.84])与ADT使用相关。
  • 纳入MRI不良特征(AUC 0.76)或放疗治疗变量(AUC 0.76)后AUC改善,但所有评估模型中仍存在显著的机构间异质性(P<.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: For men with intermediate-risk prostate cancer treated with definitive therapy, the addition of androgen deprivation therapy (ADT) reduces the risk of distant metastasis and cancer-related mortality. However, the absolute benefit of ADT varies by baseline cancer risk. Estimates of prognosis have improved over time, and little is known about ADT decision making in the modern era. We sought to characterize variability and identify factors associated with intended ADT use within the Michigan Radiation Oncology Quality Consoritum (MROQC). MATERIALS AND METHODS: Patients with localized prostate cancer undergoing definitive radiation therapy were enrolled from June 9, 2020, to June 26, 2023 (n = 815). Prospective data were collected using standardized patient, physician, and physicist forms. Intended ADT use was prospectively defined and was the primary outcome. Associations with patient, tumor, and practice-related factors were tested with multivariable analyses. Random intercept modeling was used to estimate facility-level variability. RESULTS: Five hundred seventy patients across 26 facilities were enrolled with intermediate-risk disease. ADT was intended for 46% of men (n = 262/570), which differed by National Comprehensive Cancer Network favorable intermediate-risk (23.5%, n = 38/172) versus unfavorable intermediate-risk disease (56.3%, n = 224/398; P < .001). After adjusting for the statewide case mix, the predicted probability of intended ADT use varied significantly across facilities, ranging from 15.4% (95% CI, 5.4%-37.0%) to 71.7% (95% CI, 57.0%-82.9%), with P < .01. Multivariable analyses showed that grade group 3 (OR, 4.60 [3.20-6.67]), ≥50% positive cores (OR, 2.15 [1.43-3.25]), and prostate-specific antigen 10 to 20 (OR, 1.87 [1.24-2.84]) were associated with ADT use. Area under the curve was improved when incorporating MRI adverse features (0.76) or radiation treatment variables (0.76), but there remained significant facility-level heterogeneity in all models evaluated (P < .05). CONCLUSIONS: Within a state-wide consortium, there is substantial facility-level heterogeneity in intended ADT use for men with intermediate-risk prostate cancer. Future efforts are necessary to identify patients who will benefit most from ADT and to develop strategies to standardize appropriate use.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Dykstra MP, Regan SN, Yin HM, et al. Variation in Androgen Deprivation Therapy Use Among Men With Intermediate-Risk Prostate Cancer: Results From a Statewide Radiation Oncology Quality Consortium. Int J Radiat Oncol Biol Phys. 2024. PMID: 38844140. doi:10.1016/j.ijrobp.2024.05.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。